Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.34EUR
24 Apr 2019
Change (% chg)

-- (--)
Prev Close
€74.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,323,678
52-wk High
€80.44
52-wk Low
€63.25

Select another date:

Wed, Apr 10 2019

Photo

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK, April 10 Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

UPDATE 1-FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

Exclusive: Sanofi says working on CEO succession plan

PARIS Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

March 11 The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs.

Taxotere plaintiff urges MDL judge to keep bellwether case against Sanofi intact

A woman suing Sanofi S.A. for allegedly failing to warn her and her doctor about the risk of permanent hair loss from breast cancer drug Taxotere on Wednesday sharply disputed the company's contention that she would have been prescribed the drug anyway.

Select another date: